Dr. Carl J. Danzig, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,046
Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Temple University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME109536 · TX license N2461 (first issued 2009; active) -
Retina Specialist (Ophthalmology) Physician
FL license ME109536
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Eye Physicians of Florida LLP (45 clinicians)
- Advanced Retina Institute LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,046
- Services billed
- 14,492
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 6,060 | 41 |
| Imaging of retina | 2,265 | 1,013 |
| Injection of drug into eye | 1,144 | 291 |
| Established patient problem focused exam of visual system | 903 | 438 |
| Photography of the retina | 884 | 723 |
| Unclassified drugs | 765 | 223 |
| Established patient complete exam of visual system | 761 | 682 |
| Injection, aflibercept, 1 mg | 344 | 85 |
| New patient complete exam of visual system | 119 | 119 |
| Extended exam of the back part of the eye with optic nerve drawing | 119 | 117 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vabysmo (faricimab-svoa) | 452 |
| Latanoprost Other prescribers in Plantation, FL | 253 |
| Eylea (aflibercept) | 167 |
| Brimonidine Tartrate Other prescribers in Plantation, FL | 116 |
| Izervay (avacincaptad pegol sodium/pf) | 100 |
| Eylea Hd (aflibercept) | 99 |
| Ketorolac Tromethamine Other prescribers in Plantation, FL | 86 |
| Prednisolone Acetate Other prescribers in Plantation, FL | 85 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Plantation, FL | 75 |
| Dorzolamide Hcl Other prescribers in Plantation, FL | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 150 payments worth $150,110 in total to this clinician.
| Astellas Pharma US Inc | $91,955 |
|---|---|
| Ocular Therapeutix, Inc. | $36,075 |
| Genentech USA, Inc. | $9,196 |
| Astellas Pharma Global Development | $5,155 |
| Apellis Pharmaceuticals, Inc. | $3,344 |
| Genentech, Inc. | $1,708 |
| AbbVie Inc. | $1,227 |
| Samsung Bioepis Co., LTD. | $713 |
| Compensation for services other than consulting (speaking, faculty) | $78,900 |
|---|---|
| Consulting Fee | $57,348 |
| Travel and Lodging | $9,637 |
| Food and Beverage | $4,225 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Jun 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $7,200 |
| Astellas Pharma US Inc Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $7,200 |
| Astellas Pharma US Inc Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $5,200 |
All 89 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Dec 22, 2025 | Consulting Fee Izervay · Ophthalmology | $2,600 |
| Ocular Therapeutix, Inc. Dec 10, 2025 | Consulting Fee | $500 |
| Astellas Pharma US Inc Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $7,200 |
| Astellas Pharma US Inc Dec 9, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Bonita Springs, FL | $221 |
| Astellas Pharma US Inc Dec 9, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Bonita Springs, FL | $176 |
| Astellas Pharma US Inc Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Dec 5, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Chicago, IL | $331 |
| Astellas Pharma US Inc Dec 5, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Chicago, IL | $264 |
| Astellas Pharma US Inc Dec 5, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Chicago, IL | $179 |
| Astellas Pharma US Inc Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $1,000 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $5,200 |
| Astellas Pharma US Inc Nov 7, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New York, NY | $467 |
| Astellas Pharma Global Development Nov 7, 2025 | Consulting Fee Izervay · Ophthalmology | $462 |
| Astellas Pharma US Inc Nov 7, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New York, NY | $450 |
| Astellas Pharma US Inc Nov 7, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New York, NY | $308 |
| Ocular Therapeutix, Inc. Oct 23, 2025 | Consulting Fee | $250 |
| Astellas Pharma US Inc Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Oct 21, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Tuscaloosa, AL | $363 |
| Astellas Pharma US Inc Oct 21, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Tuscaloosa, AL | $305 |
| Astellas Pharma US Inc Oct 21, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Tuscaloosa, AL | $301 |
| Ocular Therapeutix, Inc. Oct 17, 2025 | Consulting Fee | $500 |
| Genentech USA, Inc. Oct 16, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $4,275 |
| Genentech USA, Inc. Oct 16, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Orlando, FL · in-kind | $412 |
| Genentech USA, Inc. Oct 16, 2025 | Travel and Lodging Vabysmo · Immunology and Ophthalmology · travel to Orlando, FL | $263 |
| Ocular Therapeutix, Inc. Oct 15, 2025 | Consulting Fee | $2,000 |
| Astellas Pharma US Inc Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Oct 9, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to West Springfield, MA | $708 |
| Astellas Pharma US Inc Oct 9, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to West Springfield, MA | $176 |
| Astellas Pharma US Inc Oct 9, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to West Springfield, MA | $124 |
| Ocular Therapeutix, Inc. Oct 6, 2025 | Consulting Fee | $1,000 |
| Astellas Pharma US Inc Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Sep 30, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New Orleans, LA | $1,453 |
| Astellas Pharma US Inc Sep 30, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New Orleans, LA | $455 |
| Astellas Pharma US Inc Sep 30, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to New Orleans, LA | $313 |
| Ocular Therapeutix, Inc. Sep 28, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Sep 27, 2025 | Consulting Fee | $250 |
| AbbVie Inc. Sep 26, 2025 | Consulting Fee OZURDEX · EYE CARE | $1,025 |
| Ocular Therapeutix, Inc. Sep 22, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Sep 21, 2025 | Consulting Fee | $250 |
| Ocular Therapeutix, Inc. Sep 19, 2025 | Consulting Fee | $500 |
| Astellas Pharma US Inc Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $8,400 |
| Astellas Pharma US Inc Sep 18, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Reno, NV | $744 |
| Astellas Pharma US Inc Sep 18, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Reno, NV | $310 |
| Astellas Pharma US Inc Sep 18, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Reno, NV | $223 |
| Ocular Therapeutix, Inc. Aug 30, 2025 | Consulting Fee | $1,000 |
| Apellis Pharmaceuticals, Inc. Aug 29, 2025 | Consulting Fee | $2,838 |
| Apellis Pharmaceuticals, Inc. Aug 29, 2025 | Consulting Fee | $363 |
| Ocular Therapeutix, Inc. Aug 25, 2025 | Consulting Fee | $1,000 |
| Astellas Pharma US Inc Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Astellas Pharma US Inc Aug 21, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Boca Raton, FL | $28.00 |
| Astellas Pharma US Inc Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $1,000 |
| Ocular Therapeutix, Inc. Aug 11, 2025 | Consulting Fee | $1,000 |
| Astellas Pharma Global Development Aug 1, 2025 | Consulting Fee Izervay · Ophthalmology | $1,846 |
| Ocular Therapeutix, Inc. Aug 1, 2025 | Consulting Fee | $1,000 |
| Genentech USA, Inc. Jul 31, 2025 | Consulting Fee | $3,445 |
| Genentech USA, Inc. Jul 31, 2025 | Travel and Lodging travel to Long Beach, CA | $304 |
| Genentech USA, Inc. Jul 31, 2025 | Travel and Lodging travel to Long Beach, CA | $16.94 |
| Ocular Therapeutix, Inc. Jul 15, 2025 | Consulting Fee | $1,000 |
| Genentech, Inc. Jul 2, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $840 |
| Genentech, Inc. Jul 2, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $840 |
| Ocular Therapeutix, Inc. Jun 21, 2025 | Consulting Fee | $2,500 |
| Ocular Therapeutix, Inc. Jun 20, 2025 | Consulting Fee | $1,833 |
| Ocular Therapeutix, Inc. Jun 19, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Jun 18, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Jun 17, 2025 | Consulting Fee | $500 |
| Astellas Pharma US Inc Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $900 |
| Astellas Pharma US Inc Jun 7, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $7,200 |
| Astellas Pharma US Inc Jun 7, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Orlando, FL | $446 |
| Astellas Pharma US Inc Jun 7, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Orlando, FL | $293 |
| Astellas Pharma Global Development Jun 6, 2025 | Consulting Fee Izervay · Ophthalmology | $2,769 |
| Ocular Therapeutix, Inc. May 29, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. May 11, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. May 10, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. May 9, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. May 5, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Apr 27, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Apr 24, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Apr 24, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Apr 4, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Apr 1, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Mar 18, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Mar 3, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Feb 22, 2025 | Consulting Fee | $2,500 |
| Ocular Therapeutix, Inc. Feb 7, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Jan 27, 2025 | Consulting Fee | $1,500 |
| Ocular Therapeutix, Inc. Jan 20, 2025 | Consulting Fee | $500 |
| Ocular Therapeutix, Inc. Jan 20, 2025 | Consulting Fee | $250 |
| Samsung Bioepis Co., LTD. Jan 16, 2025 | Consulting Fee E301 · Ophthalmology | $713 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 8 companies. The companies reported $454,879 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - IAMD Observational Study
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. - A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Alexion Pharmaceuticals, Inc. - ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Novartis Pharmaceuticals Corporation - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim International GmbH - Phase II PAFRa in GA
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.